Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial

Maryland Medical Research Institute, Baltimore 21210.

OBJECTIVES. This report describes the survival and reinfarction rates for 2- and 3-year follow-up in the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. BACKGROUND. Patients enrolled in TIMI II were randomly assigned to an invasive (1,681 patients) or a conservative (1,658 patients) management strategy to follow receipt of intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction. METHODS. Eligibility required presentation within 4h of onset of symptoms and at least 1-mV ST segment elevation in two contiguous electrocardiographic leads. The invasive strategy group underwent cardiac catheterization 18 to 48 h after study entry and, when appropriate, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting. In the conservative strategy group these diagnostic and revascularization procedures were reserved for recurrent spontaneous ischemia or ischemia on low level exercise at the time of hospital discharge. RESULTS. Complete 2-year follow-up data are available for 3,187 patients (95.4%). Cumulative life-table rates of death or reinfarction were 17.6% for the invasive strategy group and 17.9% for the conservative strategy group (p = NS) and mortality was 8.9% and 8.7% (p = NS), respectively. Complete data are available for 1,959 (90.1%) of the 2,174 patients enrolled for 3 years. Rates of death or reinfarction were 21.0% for the invasive strategy group with 20.0% for the conservative strategy group (p = NS), with mortality of 11.5% and 11.0% (p = NS), respectively. In this cohort, the mortality was 1.3% in the 2nd year and 1.7% in the 3rd year from study entry. CONCLUSIONS. TIMI II invasive and conservative strategies resulted in similar favorable outcomes after 2 and 3 years. Mortality and reinfarction rates in the two strategies were comparable. Deaths were infrequent in the 2nd and 3rd years from study entry.

This article has been cited by other articles:

				G R Rhydwen, S Charman, and P M Schofield Influence of thrombolytic therapy on the patterns of ventricular septal rupture after acute myocardial infarction Postgrad. Med. J., July 1, 2002; 78(921): 408 - 412. [Abstract] [Full Text] [PDF]

				K P Balachandran, J Miller, A C H Pell, B D Vallance, and K G Oldroyd Rescue percutaneous coronary intervention for failed thrombolysis: results from a district general hospital Postgrad. Med. J., June 1, 2002; 78(920): 330 - 334. [Abstract] [Full Text] [PDF]

				L. Pilote, C. Lauzon, T. Huynh, D. Dion, R. Roux, N. Racine, S. Carignan, J. G. Diodati, C. Levesque, F. Charbonneau, et al. Quality of Life After Acute Myocardial Infarction Among Patients Treated at Sites With and Without On-site Availability of Angiography Arch Intern Med, March 11, 2002; 162(5): 553 - 559. [Abstract] [Full Text] [PDF]

				K. J. Mukamal, R. W. Nesto, M. C. Cohen, J. E. Muller, M. Maclure, J. B. Sherwood, and M. A. Mittleman Impact of Diabetes on Long-Term Survival After Acute Myocardial Infarction: Comparability of risk with prior myocardial infarction Diabetes Care, August 1, 2001; 24(8): 1422 - 1427. [Abstract] [Full Text] [PDF]

				S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239. [Full Text] [PDF]

				G. L. Knatterud, Y. Rosenberg, L. Campeau, N. L. Geller, D. B. Hunninghake, S. A. Forman, J. S. Forrester, F. L. Gobel, J. A. Herd, A. Hickey, et al. Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial Circulation, July 11, 2000; 102(2): 157 - 165. [Abstract] [Full Text] [PDF]

				F. J. Th. Wackers and B. L. Zaret Risk Stratification Soon After Acute Infarction Circulation, November 16, 1999; 100(20): 2040 - 2042. [Full Text] [PDF]

				P. J. Scanlon, D. P. Faxon, A.-M. Audet, B. Carabello, G. J. Dehmer, K. A. Eagle, R. D. Legako, D. F. Leon, J. A. Murray, S. E. Nissen, et al. ACC/AHA guidelines for coronary angiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1756 - 1824. [Full Text] [PDF]

				A. M. Ross, K. S. Coyne, E. Moreyra, J. S. Reiner, S. W. Greenhouse, P. L. Walker, M. L. Simoons, Y. C. Draoui, R. M. Califf, E. J. Topol, et al. Extended Mortality Benefit of Early Postinfarction Reperfusion Circulation, April 28, 1998; 97(16): 1549 - 1556. [Abstract] [Full Text] [PDF]

				M. E. Carlos, S. C. Smart, J. C. Wynsen, and K. B. Sagar Dobutamine Stress Echocardiography for Risk Stratification After Myocardial Infarction Circulation, March 18, 1997; 95(6): 1402 - 1410. [Abstract] [Full Text]

				T. Lenderink, M. L. Simoons, G.-A. Van Es, F. Van de Werf, M. Verstraete, and A. E.R. Arnold Benefit of Thrombolytic Therapy Is Sustained Throughout Five Years and Is Related to TIMI Perfusion Grade 3 But Not Grade 2 Flow at Discharge Circulation, September 1, 1995; 92(5): 1110 - 1116. [Abstract] [Full Text]